|Day Low/High||182.88 / 187.15|
|52 Wk Low/High||176.36 / 242.99|
TheStreet senior columnist Adam Feuerstein explains why Vertex Pharmaceuticals is the next big thing in biotech.
Action in individual stocks was impressive despite the struggling indices.
US stock futures are up amid earnings from GE and IBM. TheStreet's Debra Borchardt details.
Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.
Traders are jockeying for position as we await the Fed, economic data and key earnings.
Senior columnist Adam Feuerstein says earnings from Dendreon and Vertex are the next big things in biotech.
Adam Feuerstein, Sr. Columnist for TheStreet, says Vertex Pharmaceuticals is the next big thing in biotech.
Here is this week's roundup of the dumbest actions on Wall Street.
The longer this action persists, the more anxious folks will be to put idle cash to work.
Evan Lazarus of T3Live review the day's market action and sets up your trading plan for the next session.
Senior columnist Adam Feuerstein says Pfizer is the next big thing in biotech.